BREVAGenplus(R) Offers a Solution to Physicians Concerned About the Revised Breast Cancer Screening Guidelines from the American Cancer Society (ACS)

CHARLOTTE, N.C., Nov. 2, 2015 -- Phenogen Sciences, Inc., the U.S. subsidiary of Australia-based Genetic Technologies Limited (GENE) and maker of BREVAGenplus, today commented on the American Cancer Society's (ACS) recent changes to its breast cancer screening guidelines. These guidelines, which are aimed at women with an average risk of breast cancer, raised the recommended age for first mammogram to 45 and suggested women over age 55 switch to biennial mammograms. However, the recommendations also create clinical ambiguity by concluding that women between ages 40 and 44 should still have the choice to get annual mammograms, and that women 55 years and older should likewise have the opportunity to continue annual screenings.¹ BREVAGenplus, a clinically-validated, genetically-based breast cancer risk assessment test, can help physicians resolve this ambiguity by identifying which women without a family history still warrant earlier and/or more frequent screening.

Cancer Genetics, Inc. Receives Third Patent for Proprietary Genomic FHACT(R) Test, Further Advancing the Detection and Treatment of Cervical and Other HPV-Associated Cancers

• Each year in the United States more than 55 million Pap smears are performed, of which 3.5 million have abnormal or unclear results¹
• The FHACT® test will be available immediately through CGI’s expanded National Clinical Sales Force

 RUTHERFORD, N.J., Oct. 28, 2015  -- Cancer Genetics, Inc. (CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced that it has received a third U.S. patent covering FHACT® (U.S. Patent No. 9,157,129), its proprietary FISH (fluorescent in situ hybridization)-based HPV-Associated Cancer Test. FHACT® is primarily used as a diagnostic tool for the detection of cervical cancer and pre-cancers. This patent is part of a series of patents received for FHACT® that provide protections for CGI’s proprietary capabilities for the detection of HPV-associated cancers, which include cervical, anal, head and neck, penile, and vulvar cancers. Cervical cancer is one of the most common HPV-associated cancers, with approximately 528,000 new cases diagnosed annually worldwide.²

Body of Evidence Supporting the Use of Toraymyxin(TM) for Treatment of Septic Shock Continues to Grow

TORONTO, ONTARIO--(Oct 19, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (EDT.TO)(EDTXF), a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced that the medical literature supporting the use of Toraymyxin™ ("PMX") for the treatment of septic shock patients continues to grow. Peer-reviewed articles, observational studies and case reports of PMX use outside of North America conclude that this medical device is safe and effective. Upon approval, this unique treatment could potentially save tens of thousands of lives in the United States and Canada annually and solve a very significant unmet medical need.